Ensayos clínicos de Obesidad en Virginia
44 estudios sobre Obesidad buscan participantes en Virginia.
Ciudades en Virginia
- Arlington18 estudios
- Richmond11 estudios
- Charlottesville9 estudios
- Newport News8 estudios
- Norfolk5 estudios
- Winchester5 estudios
- Roanoke4 estudios
- Alexandria4 estudios
Texto oficial del estudio (inglés)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Washington Center For Weight Management And Research /ID# 282047, Arlington
- Sovah Health - Danville /ID# 282876, Danville
- Health Research Of Hampton Roads /ID# 282014, Newport News
- y 1 más
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 29 sept 2026 · NCT07752979AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Washington Cntr Weight Mgmt, Arlington
- Health Res of Hampton Roads, Newport News
- National Clin Res Inc., Richmond
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- National Clin Res Inc., Richmond
- Gastroent Consult of SW VA, Roanoke
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- York Clinical Research, LLC, Norfolk
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Manassas
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07776509AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- Washington Cntr Weight Mgmt, Arlington
- Health Res of Hampton Roads, Newport News
- Selma Medical Associates, Winchester
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT07339423A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- VCU Health - Center for Endocrinology Diabetes and Metabolism, Richmond
ReclutandoFase 3
Edades de 6 a 17 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Consultants of Southwest Virginia, Roanoke
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06937086A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Sovah Clinical Research-River District, Danville
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07589608A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Carient Heart & Vascular - Manassas, Manassas
- Carient Heart and Vascular LLC-Reston, Reston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07783802A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
- Charlottesville Medical Research, Charlottesville
- Gershon Pain Specialists, Virginia Beach
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07153471A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Manassas
- Research Site, Norfolk
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07784270Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Charlottesville Medical Research, Charlottesville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Norfolk
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Inova Cardiology - Fairfax, Fairfax
- Virginia Heart, Falls Church
ReclutandoFase 3
Edades de 45 a 99 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07037433A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Hampton
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Hampton
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Conquest Research, LLC, Arlington
- Virginia Heart, Falls Church
- Carient Heart and Vascular, Manassas
- y 2 más
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 16 sept 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Manassas Clinical Research Center, Manassas
- Centricity Research Suffolk Primary Care, Suffolk
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT07351058A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Burke
- ACCOMPLISH-2 Research Site, Manassas
- ACCOMPLISH-2 Research Site, Suffolk
ReclutandoFase 3Se aceptan voluntarios sanos
Edades de 18 a 79 · Todos los sexos · Actualizado el 11 sept 2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Selma Medical Associates, Winchester
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT07770841A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Eastern Virginia Medical School (EVMS) Medical Group, Norfolk
- Clinical Research Partners, LLC, Richmond
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07215559A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Sovah Clinical Research-River District, Danville
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 8 sept 2026 · NCT06143956AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- National Clin Res Inc., Richmond
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07533175A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Health Res of Hampton Roads, Newport News
- National Clin Res Inc., Richmond
- Selma Medical Associates, Winchester
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07745504Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Danville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Manassas Clinical Research Center Inc, Manassas
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Manassas
- Kailera Clinical Site, Richmond
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Washington Center for Weight Management and Research, Inc, Arlington
- Health Research of Hampton Roads, Newport News
- Selma Medical Associates, Winchester
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07684235Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Manassas
- Kailera Clinical Site, Richmond
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 sept 2026 · NCT07284979A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Arlington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- University Of Virginia Hospital, Charlottesville
- Carient Heart and Vascular, Manassas
- TPMG Clinical Research, Newport News
- y 4 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT07567001AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Health Res of Hampton Roads, Newport News
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT07509307A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Charlottesville Medical Research, Charlottesville
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 22 jul 2026 · NCT07477704A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Charlottesville Med Research, Charlottesville
- Health Res of Hampton Roads, Newport News
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 jul 2026 · NCT07481630Brief Inhibitory Training for Eating - Intervention
- George Mason University, Fairfax
Reclutando
Edades de 14 a 17 · Todos los sexos · Actualizado el 17 jun 2026 · NCT07592728Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- Children's Hospital of Richmond at VCU Healthy Lifestyles Center, Henrico
ReclutandoSe aceptan voluntarios sanos
Edades de 4 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT06714929Redefining BMI: The Body, Mind, and Inflammation Trial
- Virginia Commonwealth Universtity, Richmond
Reclutando
Edades de 18 a 25 · Mujeres · Actualizado el 6 may 2026 · NCT06532747A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- Vanda Investigational Site, Burke
ReclutandoFase 3Se aceptan voluntarios sanos
Edades de 18 a 65 · Todos los sexos · Actualizado el 20 abr 2026 · NCT07446439Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
- University of Virginia Medical Center, Charlottesville
ReclutandoFase 2
Edades de 12 a 21 · Todos los sexos · Actualizado el 17 abr 2026 · NCT06903923De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.